Administration of Recombinant Human Leukocyte α2-Interferon in Patients With Amyotrophic Lateral Sclerosis

Marinos C. Dalakas; Allen J. Aksamit; David L. Madden; John L. Sever

doi:10.1001/archneur.1986.00520090061018

Administration of Recombinant Human Leukocyte α2-Interferon in Patients With Amyotrophic Lateral Sclerosis

Marinos C. Dalakas, Allen J. Aksamit, David L. Madden, John L. Sever

Neurology

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Recombinant leukocyte α₂-interferon (with >98% purity) was evaluated in a pilot treatment in six patients with amyotrophic lateral sclerosis and one patient with slowly progressive postpoliomyelitis motor neuron disease. Interferon, administered subcutaneously in doses of 2 million units three times per week for four months, was ineffective in improving, arresting, or slowing the pace of progression in all the patients who were followed up for ten to 14 months after the end of therapy.

Original language	English (US)
Pages (from-to)	933-935
Number of pages	3
Journal	Archives of neurology
Volume	43
Issue number	9
DOIs	https://doi.org/10.1001/archneur.1986.00520090061018
State	Published - Sep 1986

ASJC Scopus subject areas

Arts and Humanities (miscellaneous)
Clinical Neurology

Access to Document

10.1001/archneur.1986.00520090061018

Cite this

@article{e201d407246d463f9568b05569daee7f,

title = "Administration of Recombinant Human Leukocyte α2-Interferon in Patients With Amyotrophic Lateral Sclerosis",

abstract = "Recombinant leukocyte α2-interferon (with >98% purity) was evaluated in a pilot treatment in six patients with amyotrophic lateral sclerosis and one patient with slowly progressive postpoliomyelitis motor neuron disease. Interferon, administered subcutaneously in doses of 2 million units three times per week for four months, was ineffective in improving, arresting, or slowing the pace of progression in all the patients who were followed up for ten to 14 months after the end of therapy.",

author = "Dalakas, {Marinos C.} and Aksamit, {Allen J.} and Madden, {David L.} and Sever, {John L.}",

year = "1986",

month = sep,

doi = "10.1001/archneur.1986.00520090061018",

language = "English (US)",

volume = "43",

pages = "933--935",

journal = "Archives of neurology",

issn = "0003-9942",

publisher = "American Medical Association",

number = "9",

}

TY - JOUR

T1 - Administration of Recombinant Human Leukocyte α2-Interferon in Patients With Amyotrophic Lateral Sclerosis

AU - Dalakas, Marinos C.

AU - Aksamit, Allen J.

AU - Madden, David L.

AU - Sever, John L.

PY - 1986/9

Y1 - 1986/9

N2 - Recombinant leukocyte α2-interferon (with >98% purity) was evaluated in a pilot treatment in six patients with amyotrophic lateral sclerosis and one patient with slowly progressive postpoliomyelitis motor neuron disease. Interferon, administered subcutaneously in doses of 2 million units three times per week for four months, was ineffective in improving, arresting, or slowing the pace of progression in all the patients who were followed up for ten to 14 months after the end of therapy.

AB - Recombinant leukocyte α2-interferon (with >98% purity) was evaluated in a pilot treatment in six patients with amyotrophic lateral sclerosis and one patient with slowly progressive postpoliomyelitis motor neuron disease. Interferon, administered subcutaneously in doses of 2 million units three times per week for four months, was ineffective in improving, arresting, or slowing the pace of progression in all the patients who were followed up for ten to 14 months after the end of therapy.

UR - http://www.scopus.com/inward/record.url?scp=0022482174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022482174&partnerID=8YFLogxK

U2 - 10.1001/archneur.1986.00520090061018

DO - 10.1001/archneur.1986.00520090061018

M3 - Article

C2 - 3741210

AN - SCOPUS:0022482174

SN - 0003-9942

VL - 43

SP - 933

EP - 935

JO - Archives of neurology

JF - Archives of neurology

IS - 9

ER -

Administration of Recombinant Human Leukocyte α2-Interferon in Patients With Amyotrophic Lateral Sclerosis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this